![](https://investorshub.advfn.com/uicon/477123.png?cb=1533675489)
Monday, February 13, 2017 5:24:55 PM
Love your projections but 20% royalty on a generic drug ..... I don't think is reasonable to use.
Bottomline generic royalties are much lower. You said yourself you came up with 10% royalty on focalin during the exclusivity period and lower thereafter. So I'm not certain how you are starting at 20%. The high end royalties are only in play when there is licensing of groundbreaking IP involved. In the generic space of the ANDA candidates, there is no groundbreaking differentiator for IPCI IMO.
Amigo Mike
20% royalties is the least one should expect not the most... and 40% to 50% would not be uncommon for a product that is already FDA approved... I used 20% to get the skeptics on board... but I guess you're beyond reach.
I was going to say we are of differing opinions... and then I came across Doog's post where Mackie seems far more in agreement with my estimation than yours.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128671703
According to Symphony Health Solution, sales in the U.S. for 12 month ended August 2015 for brand Seroquel XR were approx.
US$1.2BN. We are assuming market size would decrease by 35% to US$780M per year after its genericization. We estimate IPCI’s
generic Seroquel XR would take max. 9% of the market and after that the market share would drop by 20% on yearly basis. We are
assuming a gross margin of 80% and that IPCI and Mallinckrodt would evenly split the gross profit. Our estimates of IPCI’s share
from its generic Seroquel XR sales in the U.S. from 2017 to 2020 are US$13.5M, US$21.2M, US$17.0M, and US$13.6M, respectively.
My Note: Evenly splitting the gross profit where the gross margin is 80% is equal to 40% Pure Profit Royalties.
Recent IPCI News
- Suspension de la négociation par l'Organisme canadien de réglementation des investissements - IPCI • PR Newswire (Canada) • 03/06/2024 12:55:00 PM
- Canadian Investment Regulatory Organization Trading Halt - IPCI • PR Newswire (Canada) • 03/06/2024 12:51:00 PM
FEATURED Element79 Gold Corp Announces 2024 Clover Work Plans & Nevada Portfolio Updates • Sep 10, 2024 11:00 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM
Nightfood Holdings Inc. Completes Major Step on Uplist Journey by Closing Strategic All-Stock Acquisition of CarryoutSupplies.com • NGTF • Sep 10, 2024 8:15 AM
Element79 Gold Corp. Announces Sale of 100% Interest in Elder Creek, North Mill Creek, and Elephant Projects to 1472886 B.C. Ltd. • ELEM • Sep 9, 2024 9:34 AM
North Bay Resources Commences Gold Shipments, Fran Gold Project, British Columbia; Enters Taber Gold Mine JV, Sierra County, California • NBRI • Sep 9, 2024 9:15 AM
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM